Alliance Global Partners Initiates Coverage on DarioHealth (NASDAQ:DRIO)

Research analysts at Alliance Global Partners assumed coverage on shares of DarioHealth (NASDAQ:DRIO) in a note issued to investors on Wednesday. The firm set a “buy” rating and a $12.00 price target on the stock. Alliance Global Partners’ target price would suggest a potential upside of 67.13% from the company’s current price.

A number of other analysts have also recently commented on the stock. TD Cowen dropped their price objective on DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. Stifel Nicolaus reissued a “buy” rating and issued a $10.00 target price on shares of DarioHealth in a research note on Thursday, May 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of DarioHealth in a report on Friday, July 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, DarioHealth currently has a consensus rating of “Hold” and an average target price of $10.00.

DarioHealth Stock Down 2.4%

DarioHealth stock opened at $7.18 on Wednesday. The company’s 50 day simple moving average is $7.09 and its 200 day simple moving average is $8.16. DarioHealth has a fifty-two week low of $5.84 and a fifty-two week high of $17.74. The firm has a market capitalization of $52.72 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.31 and a quick ratio of 1.92.

DarioHealth (NASDAQ:DRIO) last issued its earnings results on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.37. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.92 million. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. As a group, sell-side analysts anticipate that DarioHealth will post -3.12 EPS for the current year.

Insider Activity at DarioHealth

In related news, Director Dennis Matheis acquired 14,430 shares of the business’s stock in a transaction that occurred on Thursday, July 23rd. The shares were acquired at an average cost of $6.93 per share, with a total value of $99,999.90. Following the transaction, the director owned 43,026 shares of the company’s stock, valued at $298,170.18. The trade was a 50.46% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DarioHealth

Large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new stake in shares of DarioHealth in the fourth quarter valued at about $35,000. BlackRock Inc. bought a new position in shares of DarioHealth during the second quarter worth about $249,000. Geode Capital Management LLC grew its holdings in shares of DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after buying an additional 31,063 shares in the last quarter. XTX Topco Ltd raised its position in DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after buying an additional 43,513 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in DarioHealth in the 2nd quarter valued at approximately $4,030,561,000. Institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.